A stent is a medical device designed to serve as a temporary or permanent internal scaffold to maintain or increase the lumen of a body conduit. Metallic coronary stents were first introduced to prevent arterial dissections and to eliminate vessel recoil and intimal hyperplasia associated with percutaneous transluminal coronary angioplasty. The stent application range has expanded as more experience was gained, and encouraging results have been obtained in the treatment of vascular diseases. Stents are currently used for support of additional body conduits, including the urethra, trachea, and esophagus. The rationale for bioresorbable stents is the support of a body conduit only during its healing process. The stent mass and strength decrease with time, and the mechanical load is gradually transferred to the surrounding tissue. Bioresorbable stents also enable longer term delivery of drugs to the conduit wall from an internal reservoir and abolish the need for a second surgery to remove the device. The present review describes recent advances in bioresorbable stents, focusing on drug-eluting bioresorbable stents for various applications. Controlled release of an active agent from a stent can be used to enhance healing of the surrounding tissues, to increase the implant's biocompatibility, as well as to help cure certain diseases. Because a lot of research in this field has been done by us, examples for these functions are described based mainly on developments in our laboratories. 
INTRODUCTION: MEDICAL SUPPORT DEVICES (STENTS) FOR VARIOUS APPLICATIONS Coronary Stents
Coronary stenting has become an established mode of treatment in percutaneous transluminal coronary interventions. It has been shown to reduce late restenosis relative to conventional balloon angioplasty (1) (2) (3) . Early designs, including the Wallstent (Schneider), Palmaz-Schatz ( Johnson & Johnson), Wiktor (Medtronic), and Gianturco-Roubin (Cook) stents have been replaced by the Micro (AVE), Multilink (ACS), and others (4) (5) (6) (7) . The metals used to prepare these stents are selected for strength, elasticity, and malleability or shape memory. Stainless steel, tantalum, and nitinol alloys are among the most commonly used materials (6) (7) (8) (9) . Nitinol offers superelastic and thermal shape memory properties, which allow self-expansion of the stent during deployment and thermally induced collapse for theoretical removal procedures (10) .
The incidence of restenosis remains high despite technical and mechanical improvements. This restenosis is a result of in-stent neointimal hyperplasia caused by proliferation and migration of vascular smooth muscle cells (VSMCs) induced by vessel wall injury (11) . The pathology of restenosis stems from a complex interaction between cellular and acellular elements of the vessel wall and the blood (12) . Some antiproliferative and antiinflammatory agents have been shown to elute slowly from polymer coatings and to be associated with reduced neointimal formation in animal models. Two antiproliferative agents, paclitaxel (13, 14) and sirolimus (15) , have been used in humans with promising preliminary results.
Paclitaxel is a natural or semisynthetic diterpene composed of a rigid texane ring and a flexible side chain. It is an antineoplastic agent (16, 17) . However, it is potentially cardiotoxic, and the dose of paclitaxel that can be delivered safety has yet to be resolved (18, 19) . Paclitaxel has been shown to markedly attenuate stent-induced intimal thickening of the lumen (20, 21) . Paclitaxel's antiproliferative effect is reversible (22) . Its short cellular residence time (1 h), along with the reversible antiproliferative activity, suggests that it should be formulated in sustained-release dosage form (23) . Sirolimus (rapamycin) is a carbonyl lactonelactam macrolide that has been shown to inhibit VSMC growth. This inhibition has been reported to be concentration dependent, with a threshold limit of 16.7 ng/ml (24) . Sirolimus has been shown to be effective with a remarkable restenosis rate of almost 0% (25) (26) (27) . However, some criticism has been expressed regarding the absence of data in complex lesions, as well as long-term data (28) . Results of the RAVEL and SIRIUS trials demonstrated that sirolimus-eluting stents effectively inhibit restenosis in humans (29, 30) . The TAXUS trials revealed significant inhibition of coronary stenosis by paclitaxel (31) (32) (33) (34) . Drug-eluting polymer-coated stents have thus moved into the limelight as vehicles for local drug administration (35) .
Other Uses for Stents
The range of stent applications has expanded as more experience has been gained and following encouraging results in the treatment of vascular diseases. Stents have been used for treating urethral obstructions caused by benign prostatic hyperplasia and for treating benign or malignant tracheobronchial obstructions. They have also been used for supporting the neonatal trachea in tracheal malacia; for treating benign and malignant esophageal, gastrointestinal, and bile duct strictures; and for treating (stents and stent-grafts) arterial dissections, aneurysms, and various neurovascular diseases.
Stents in urology.
Stents have been used to prevent urine retention following thermal treatment of benign prostatic hyperplasia (BPH) by various means, including transurethral microwave therapy and direct vision laser ablation of the prostate. Several stent designs were shown to prevent obstruction of the prostatic urethra and restricture of the anterior urethra. These stents include the Barnes, Finnish biodegradable self-reinforced polyglycolic acid (SR-PGA) spiral; the Nissenkorn; and the Trestle stents (36) (37) (38) . In clinical studies, researchers have used biodegradable stents to treat benign prostatic hyperplasia. The results obtained yield more positive outcomes compared with those using suprapublic catheters (39) (40) (41) (42) (43) . Selfreinforced poly(l-lactic acid) (PLLA) bioresorbable spiral stents are also undergoing evaluation for use in the anterior and posterior urethra and in the upper urinary tract for preventing urinary retention and for repairing local urethral trauma or defects (44, 45) .
Stents for management of tracheobronchial obstruction. Tracheobronchial obstruction owing to either benign or malignant disease causes significant morbidity and mortality. Metal stents, which were originally developed for the vascular system, have been adapted for lesions involving the tracheobronchial tree and include the Gianturco-Z (William Cook Europe), Palmaz (Johnson & Johnson), Strecker (Boston Scientific), Ultraflex (Boston Scientific), and Wallstent (Boston Scientific) stents (46) . These stents were used successfully for treating patients with bronchogenic cancer, inoperable esophageal tumors, primary tracheal tumors, and metastatic malignancies. Bioresorbable external tracheal stents have been investigated for treating pediatric tracheal malacia, for solving the problem of limited tracheal growth in children with rigid external fixation, and for avoiding the necessity of a second procedure for removing the synthetic material (46) (47) (48) . Metal stents and nonexpandable tubular stable (nondegradable) polymeric stents were tried as internal stents to treat infants with tracheomalacia (49, 50) . The results from these studies suggest that stenting is a promising method for treating tracheal obstruction.
Stents in the esophagus and gastrointestinal tract. Many malignant and benign esophageal and gastrointestinal strictures can be treated by minimally invasive alternatives to surgery, including the use of stents. The most commonly used stents in the esophagus and in gastrointestinal tract are the Esophacoil (Instent), Flamingo (Boston Scientific), Gianturco-Z (William Cook Europe), Ultraflex (Boston Scientific), and Wallstent (Boston Scientific) stents. These stents have generally been shown to be effective in relieving esophageal dysphagia (51) (52) (53) , a success that has led to the employment of stents to manage lesions of the gastrointestinal tract, including the stomach, pylorus, duodenum, upper small intestine, and colon (51, 52) . Use of bioresorbable materials for the esophageal stent is currently being explored.
BIORESORBABLE POLYMER STENTS
Bioresorbable polymeric stents have attracted much attention as alternatives to metallic stents. There are several reasons for fabricating a stent composed of a biodegradable polymeric material. Bioresorbable polymeric vascular stents have the potential to remain in situ for a predicted period of time, keeping the vessel wall patent and then degrading to nontoxic substances. Accumulating evidence indicates that the use of a bioresorbable coronary stent dramatically decreases the need for a prosthesis after six months (54) . Bioresorbable stents are preferable for treatment of tracheomalacia in newborns and infants because removal surgery is not necessary. Furthermore, bioresorbable stents can be used as support devices as well as platforms for drug and protein delivery to the conduit wall in all of the above-mentioned applications.
Bioresorbable Polymers Used in Polymeric Stents
PLLA, PGA, poly ε-caprolactone (PCL), and poly-d,l-lactic acid (PDLLA) are the most frequently used aliphatic poly(α-hydroxy-acids) for preparing bioresorbable stents (55) (56) (57) . The semicrystalline PLLA and PGA have high initial tensile strength, permitting a robust mechanical design. The PLLA total degradation time is approximately 24 months, whereas that of PGA is 6-12 months ( Table 1) . PLLA is one of the most important biodegradable polymers, and is used in a wide range of clinical applications, including devices for orthopedic (58) (59) (60) and cardiovascular surgery (61) , sutures (62) , and drug-delivering implants (63, 64) . This polymer is a very good choice, especially for the first three above-mentioned applications, where high mechanical strength and toughness are required. PLLA can be formed into fibers, films, tubes, and matrices using standard processing techniques such as molding, extrusion, spinning, and solvent casting (62) . PCL is also a semicrystalline polymer with a relatively high degree of crystallinity (similar to PLLA and PGA). However, it exhibits lower strength and modulus than PLLA and PGA owing to its low glass transition temperature (below room temperature, see Table 1 ). PDLLA is actually a random copolymer that consists of l-lactic acid and d-lactic acid monomers. It is therefore amorphous and cannot exhibit crystalline structures. Its strength and modulus are lower than those of PGA and PLLA. Polydioxanone (PDS) has gained increasing interest in the medical and pharmaceutical fields owing to its excellent biocompatibility (62) . Although it is a semicrystalline polymer, it also exhibits lower strength than PLLA and PGA because it has a low glass transition temperature, similar to PCL. We are the first research group to investigate stents made of the PDS polymer. The main results found for these stents are presented in Drug and Protein-Loaded Bioresorbable Polymer Stents, below. Useful combinations of the above-mentioned materials (copolymers and blends) can be created to alter the mechanical properties and drug-release profiles of bioactive agents from polymeric structures based on these polymers. For example, 10/90 PDLGA, a random copolymer that contains 90% glycolic acid and 10% lactic acid, has relatively high strength but is more flexible than PGA and degrades faster. Other PDLGA formulations that contain relatively high lactic acid contents, such as 85/15 PDLGA, 75/25 PDLGA, and 50/50 PDLGA, are amorphous. Therefore, they do not exhibit high strength and modulus. However, they can be used for support in cases that do not require high strength, such as in neural stents.
All above-mentioned materials degrade principally by simple hydrolysis of the ester bond in the polymer backbone. Partial chain scission degrades the polymer to 10-40 μm particles. These particles can be phagocytized and metabolized to carbon dioxide and water, which are, of course, fully resorbed. The polymer's degradation time is a function of its chemical structure and molecular weight. Crystallinity contributes to a higher degradation time because crystalline domains are denser than amorphous domains and water molecules cannot penetrate them easily. Table 1 demonstrates that a relatively small number of polymers provides a large variety of degradation times for various medical support applications.
Bioresorbable Stents for Various Applications
Several bioresorbable stents for various applications have been reported (65, 66) . Kemppainen et al. (65) and Multanen et al. (67) reported spiral PLLA stents, and Brauers et al. (66) described tubular PDLLA and poly(DL-lactic-co-glycolic acid) stents, both for urethral applications. None of these stents is expandable.
Several early designs of expandable bioresorbable stents have been developed as alternatives to metallic vascular stents (68) (69) (70) (71) (72) (73) (74) (75) (68, 69) . They investigated several biodegradable polymers and chose PLLA as the stent material. This Duke University stent was constructed of a specialized PLLA polymer woven into a diamond-braided pattern from eight polymeric strands. It was designed to withstand compression pressures of up to 1000 mm Hg (the Palmaz-Schatz stent can withstand pressures of 300-500 mm Hg and maintain its radial strength for one month). In vivo studies demonstrated minimal thrombosis and inflammatory responses, and moderate neointimal growth. Gao et al. (70) reported the Tianjin/Beijing stent, a PDLLA/PCL stent with an inner heparin layer, deployed with a balloon catheter and employed heating and pressurization. This stent produced mild neointimal proliferation in swine carotid artery models at two months. Yamawaki et al. (71) reported a Kyoto University PGA coil stent, which exhibited thrombus deposition in canine implant studies, but no subacute closure. Nuutinen et al. (74) developed knitted PLLA and 80/20 PDLGA stents with mechanical properties similar to those of commercially available metallic stents. They found that the knitting geometry has a marked effect on the stents' mechanical properties. Such knitted bioresorbable stents are more suitable for urological, gastrointestinal, and tracheo-bronchial indications, where the size of the delivery device is not critical, as opposed to peripheral vascular or even coronary indications, for which a small-diameter delivery device is critical. Saito et al. (75) , for example, studied knitted stents in a rabbit trachea model.
DRUG AND PROTEIN LOADED BIORESORBABLE POLYMER STENTS

Fiber-Based Stents
Drug-eluting fiber-based stents have been developed mainly for blood vessel support, but the stent designs can be used also for ureteral support.
Vascular stents. Tamai et al. (72, 76) described the Igaki/Tamai stent, a bioresorbable balloon expandable zigzag coil design based on a PLLA monofilament. The thickness of the stent strut is 0.007 inches (0.17 mm) and the stent surface area is 24% at an arterial diameter of 3.0 mm. The stent has a self-expanding capacity, with an expansion range of up to 4.5 mm. This bioresorbable stent combines the features of a thermal self-expandable and a balloon expandable stent. The stent initially autoexpands in response to the heat transmitted by a delivery balloon inflated with a 70
• C contrast-water mixture (50 • C at the balloon site). Subsequent expansion is obtained by inflation at a moderate to high pressure (6 to 14 atm). This stent will continue to expand to its nominal size within the following 20 to 30 min at 37
• C. The most important and unique innovation made by Tamai et al., compared with prior investigators, is the change in stent design from a knitted pattern to a zigzag helical coil design.
The success of bioresorbable polymeric stents depends not only on the biocompatibility of the stent material but also on the ability of the manufactured stent itself, including the stent design, the scaffolding strength, the biodegradation period, etc.
Vessel wall injury causes neointimal proliferation (77) , and the severity of vessel injury is strongly correlated with neointimal thickness and the percentage of stenosis after balloon angioplasty or stenting (78) . The stent design may reduce the extent of vessel wall injury caused by the stent implantation and may influence the neointimal proliferation and the inflammatory response. Animal studies of the Igaki/Tamai stents have demonstrated that the PLLA coil stent reduced the percentage of stenosis in porcine coronary arteries at 2 weeks from 64% to 19%, compared with the PLLA knitted type stent (79) . Minimal neointimal hyperplasia was found within the PLLA coil stents, whereas moderate to severe neointimal hyperplasia was observed in knitted PLLA stents. The PLLA coil stents also exhibited long-term biocompatibility with a minimal inflammatory response in porcine coronary arteries after 16 weeks (80, 81) . Unlike stents used in previous studies, the Igaki/Tamai stent was made from a high-molecular-weight PLLA that resulted experimentally in a minimal inflammatory response, compared with that observed in previous reports. In this study, 25 stents were deployed successfully in 15 patients. No stent thrombosis or major cardiovascular events occurred within 30 days. After 6 months, restenosis occurred in 10.5% of the patients and target lesion revascularization occurred in 6.7%. This study actually provided the first report on immediate and 6-month results following implantation of a bioresorbable PLLA stent in humans.
Tranilast [(N-(3,4-dimethoxycinnamoyl) anthranilic acid] is an antiallergic drug that also inhibits the migration and proliferation of VSMCs induced by plateletderived growth factor and transforming growth factor β1 (12, 82) . Tranilast was found to significantly suppress vascular intimal hyperplasia in rabbit artery after balloon injury (83, 84) and in pig coronary arteries after balloon angioplasty and stent implantation (85) . The tranilast-eluting Igaki-Tamai stent was made of a PLLA monofilament mixed with tranilast, and its shape was similar to that of the regular Igaki-Tamai stent without the drug. The radial compression strength of the drugloaded stent was approximately 10% lower than that of the neat stent.
Drug-mixed polymer stents can be loaded with larger amounts of drug than can drug-coated stents because the polymer stent struts can contain the drug. Tsuji et al. (35) compared the tranilast content in the tranilast-eluting Igaki-Tamai stent with that in a tranilast-coated Palmaz-Schatz stent that was coated with a 20-40 mm layer of tranilast-mixed PCL. The tranilast content of the former was found to be at least four times higher than that of the latter. The authors developed three types of tranilasteluting stents: a noncoated stent that can release tranilast rapidly, a PCL-coated stent for relatively slow release of tranilast through the PCL barrier layer, and a stent with a tranilast-loaded PCL coating designed to rapidly release the drug followed by a slower release through the PCL layer. The authors stated that clinical experiments are necessary to elucidate these stents' safety and efficacy.
Uurto et al. (86) evaluated in vivo a new fiber-based drug-eluting bioresorbable vascular stent, with respect to biocompatibility, neointimal hyperplasia formation, and reliability. Monofilaments made of a polymer consisting 96% l-lactic acid and 4% d-lactic acid were manufactured by melt spinning. The stents were formed from a mesh design consisting of 16 monofilaments braided over a mandrel. These stents were coated 50/50 with two bioactive agents: dexamethasone and simvastatin. Both PCL and a polymer containing 50% l-lactic acid and 50% d-lactic acid were used as coating materials. The in vivo results (pig experiments) indicated that all stented arteries were angiographically patent. The dexamethasone-loaded stents decreased the mean luminal diameter compared to other stents and they induced minimal intimal hyperplasia. The vascular injury scores demonstrated only mild vascular trauma for all studied stents. Hence, the authors concluded that bioresorbable polymer stents appear to be biocompatible and reliable, and can be used as a local drug delivery vehicle. The findings showed a need for further investigation to prove the efficacy and safety of this new biodegradable drug-eluting stent.
The two fiber-based drug-eluting bioresorbable vascular stents described above demonstrated promising results. Other fiber-based vascular stents were developed by companies, and their studies are in progress. The growing number of such stents include, for example, the paclitaxel-loaded REVA stent (developed by REVA Company) and a stent developed by TissueGen and Endovasc companies.
PLLA multiple-lobe vascular stents. A fiber-based expandable stent design has been developed and studied in our laboratory (56, 87, 88) . This stent is prepared using a linear, continuous coil array principle, by which four furled lobes convert to a single large lobe upon balloon expansion (Figure 1) . Melt-extruded fibers with a 0.15 mm diameter were woven continuously around a four-mandrel array (one central, three peripheral) into a four-lobe configuration. Three longitudinal fibers were interwoven and glued to the coil for mechanical support. After fabrication, a conventional angioplasty balloon catheter is inserted in the central lobe and the stent can be deployed at the target site. The fully expanded stent has a helical coil structure with three longitudinal reinforcing fibers (Figure 1) . The stents' initial and final diameters are adjustable.
The bioresorbable fibers were made from a relatively high-molecular-weight PLLA (RESOMER TM L21, Boehringer Ingelheim, Germany) with an inherent viscosity of 3.6 dL/g in CHCl 3 at 30
• C. This polymer was melt spun at 190
• C and drawn at 80
• C to draw ratios of 3:1 to 8:1, to create fibers with good tensile mechanical properties. The undrawn fiber is weak and almost cannot be handled. The yield stress, ultimate tensile strength, and young modulus increased dramatically as the draw ratio increased and the maximal strain decreased, i.e., the fiber became stronger, tougher, and more brittle. These changes occur mainly due to the structural changes that lead to an increase in the polymer's degree of crystallinity (87). The 8:1 drawn fibers exhibited the highest tensile strength (980 MPa) and modulus (4.9 GPa) together with good ductility (50% strain). Most of the studied stents were therefore prepared from these fibers.
Stents with a length of 15 mm, a final (dilated) diameter of 3.0 mm, and a predilated diameter of 1.8 mm were used in this study. Most of the study focused on single-fiber stents. However, PLLA double-fiber stents were also investigated. Each dilated coil stent contained 12 loops, each bonded to three longitudinal support fibers, i.e., 36 binding points per single-fiber stent and 72 binding points per double-fiber stent. The initial radial compression strength of the dilated form of both types of stents exceeded 200 KPa. It should be mentioned that the maximal pressure that can be applied using our radial compression chamber is 200 KPa (87). Higher pressures could therefore not be measured.
The stents were immersed in PBS at 37
• C and samples were removed periodically to investigate the effect of in vitro degradation on their mechanical properties. The mode of failure observed was rupture of binding points, where the longitudinal support fibers were glued to the coil. The radial compression pressure needed to create a rupture of at least one binding point as a function of degradation time is presented in Figure 2 . The number of ruptures (binding points that failed) for each degradation time is indicated in parentheses. The PLLA stents were studied for 20 weeks. Both single-and double-fiber types of stents did not undergo any failure throughout the first eight weeks of exposure to an aqueous medium. Afterward, the radial compression pressure required to create a rupture at the binding points exhibited a linear decrease with time and the number of ruptures increased with time (Figure 2) . Because the double-fiber design has more binding points than the single-fiber design, each binding point of the former is exposed to a smaller pressure. Thus, a higher total pressure is required to fail the double-fiber stent. These stents generally exhibited good radial compression endurance. They resisted at least 150 KPa (approximately 75% of the initial strength) and exhibited only few rupture points, whereas most of the binding points remained intact. The combination of the suggested design and the relatively high-molecular-weight PLLA may thus be applicable for supporting blood vessels for at least 20 weeks and was chosen for further studies. Bioresorbable stents can simultaneously support blood vessels and serve as drug/protein delivery platforms. Certain drugs, such as steroids, can be incorporated into the PLLA fiber during melt processing. However, only small drug quantities (less than 5% w/w) can be incorporated in dense polymeric structures such as fibers without having an adverse effect on the mechanical properties of the fiber and the stent. Furthermore, most drugs and all proteins are destroyed when exposed to the high melt processing temperature. To solve this problem, we developed and studied novel drug-loaded composite fibers (87, (89) (90) (91) (92) and stents prepared from these fibers. These unique fibers actually resemble sutures (Figure 3a) and contain two sections: (a) a dense core fiber with good tensile mechanical properties (high strength and good flexibility), such as the fibers that were described here, and (b) a porous shell, i.e., a bioresorbable coating that contains the drug molecules. This section is prepared via emulsions using mild processing conditions. Two types of such core/shell fiber structures were developed and studied: a shell made of a highly porous foam-like structure [prepared using the single emulsion technique (89, 90, 92) ] as presented schematically in Figure 3b , and a shell made of microspheres [prepared using the double emulsion technique (87, 91) ] as presented schematically in Figure 3c .
Protein-loaded bioresorbable microspheres were developed and bound to the PLLA fibers and stents. These microsphere reservoirs, which were prepared by the double emulsion technique, can be loaded with biologically active aqueous or nonaqueous molecules. Because mild materials and processing steps are used, these microspheres can be loaded with all drugs, proteins, and gene transfer vectors. The processing conditions can be controlled to yield single-reservoir or multiple-reservoir microspheres, as shown in Figure 4 . The microspheres are well attached to the fibers, as seen in Figure 4a . The initial radial compression strength of all types of microsphere-loaded stents exceeded 200 KPa. This indicates that the partial dissolution of the surface layers that was performed to enable microsphere attachment to the fiber had practically no affect on the strength of the stent (87) . It has been demonstrated that the microsphere structure strongly affects the release profile of the agent from the microspheres and from the microsphere-loaded stents (87, 91) . In one of our experiments, four types of microspheres were prepared from poly(DL-lactic-coglycolic acid) consisting of 75% DL-lactic acid and 25% glycolic acid (75/25 PDLGA). Two of these microsphere types had a relatively low initial molecular weight (inherent viscosity 0.35 dL/g, ∼43,000 Daltons) and two had a medium initial molecular weight (inherent viscosity 0.69 dL/g, ∼118,000 Daltons). Each of these two types of microspheres was prepared twice, once with a thin wall and once with a thick wall, as presented in Figures 4b and 4c , respectively. The microspheres' wall thickness can be controlled by choosing the proper relative quantities of water and polymer phases of the double emulsion (87) . Albumin, an inexpensive protein, was encapsulated in the microspheres. Albumin was chosen to serve as a model for controlled release of water-soluble agents such as certain drugs and proteins as well as viral gene transfer vectors from the stent. Most of the albumin was found to be encapsulated in these 10-70 μm microspheres (mean efficiency of 85%). The cumulative albumin release profiles from the four types of microsphere-loaded stents are presented in Figure 5a . In general, a burst effect is accompanied by linear cumulative release profile, as expected for a single-reservoir system, such as these microspheres. The microspheric single reservoirs enable effective protein release from the stents. The drug release rate increased with the decrease in the microsphere's initial molecular weight owing to a higher degradation rate. Furthermore, the thick microsphere shell was found to be effective in reducing the burst effect. Multireservoir microsphere types (Figure 4d,e) are currently being studied, in addition to drug release from stents loaded with single-reservoir microspheres. It has been demonstrated that a low mixing rate of the internal emulsion results in relatively small microspheres with numerous small reservoirs inside (91) , as presented in Figure 4e . This unique matrix-like structure, which was obtained owing to a reduced solvent evaporation rate, enabled a relatively low burst release and a more moderate release profile (Figure 5b) .
Current research focuses mainly on the development of a method for incorporating non-water-soluble drugs, such as paclitaxel, in this stent design. As explained in the introduction (see Coronary Stents, above), paclitaxel is an antiproliferative drug that can prevent restenosis by inhibiting vessel smooth muscle cell proliferation (93) . Effective controlled release of the drug molecules from the stent to the blood vessel wall is desired. Slow-release paclitaxel applied perivascularly totally inhibits intimal hyperplasia and prevents lumenal narrowing following balloon angioplasty.
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Studies indicate the need for controlled paclitaxel release owing to its narrow toxictherapeutic window and highly hydrophobic nature (94) . The results presented here indicate that the microspheric reservoirs enable effective drug release from the stents. However, because the release rate of the described systems was relatively slow and the chosen active agent (paclitaxel) is not water soluble, we decided to focus on the development and study of highly porous bioresorbable fiber structures, as described in Figure 3b , that will be used to build stents. The shell section of such fibers is expected to degrade much faster than the microspheres, and as a result they will release a non-water-soluble drug within 2-4 weeks, as desired for this application (95, 96) . SEM micrographs showing a general view and a cross section of such fibers are presented in Figure 6a ,b. This research is in progress, and it has already been SEM micrographs of a core/shell fiber structure consisting of a PLLA core fiber coated with a porous PDLGA structure: (a) general view, (b) part of a cross section.
found that the paclitaxel release profile from such fibers generally exhibits a release profile typical for diffusion-controlled systems (92) . The active agent's content and the polymer content of the emulsion's organic phase demonstrated a significant effect on both the shell microstructure and on the release profile, whereas the emulsion's organic:aqueous phase ratio affected these fiber characteristics only in certain cases.
Bioresorbable multilobe stents based on other polymers for short-term applications. Procedures to remove kidney stones can be extremely painful and often include the insertion of a nondisposable plastic or ruber ureteral stent to prevent further damage of the urinary tract and promote healing. Presently, most ureteral stents require a second (cystoscopy) procedure for removal. By inserting a bioresorbable stent at the time of the first procedure, one could eliminate the pain and expense of the second procedure. At the present time, there are no bioresorbable urinary stents available in the market. Such stents should degrade much faster than PLLA ones.
Our PLLA stents demonstrated excellent initial strength and strength retention for 20 weeks. Because the PLLA's degradation rate is relatively slow, other polymers should be considered for moderate and short-term applications, such as in urinary applications. We therefore also investigated polydioxanone (PDS) and poly(glycoliccoε-caprolactone) (PGACL), which exhibited moderate and fast degradation rates, respectively (97) .
PDS has gained increasing interest in the medical and pharmaceutical fields owing to its excellent biocompatibility (62) . It has been introduced into the market as a suture and as a bone pin [ORTHOSRB (98, 99) ]. Its total degradation time is 6-12 months. PGACL is a block copolymer of glycolide and ε-caprolactone. This unique bioresorbable polymer degrades completely within 3-4 months. It offers reduced stiffness compared with pure poly(glycolic acid) and has been introduced into the market by Ethicon as a monofilament suture (Monocryl). The initial tensile mechanical properties of these two fibers compared with those of PLLA, as measured by us, are presented in Table 2 . PLLA demonstrated a very high tensile strength and modulus and a moderate ultimate strain (ductility), whereas PDS exhibited moderate tensile strength and modulus and a relatively high ductility, and PGACL exhibited high tensile strength and ductility and moderate modulus. These three polymers are thus totally different from each other and exhibit a relatively large variety of initial mechanical properties. It should be emphasized, again, that in order to be able to produce stents from these fibers they should combine relatively high strength with sufficient ductility and flexibility. All three fiber types exhibited these required properties. The weight retention profiles of the three fibers are presented in Figure 7a . Time (weeks) PLLA did not exhibit any weight loss following exposure to an aqueous medium during the six weeks of study, whereas PDS lost approximately 2% of its initial weight and PGACL gradually lost 30% of its initial weight within 6 weeks of immersion in an aqueous medium. The radial compression strength as a function of degradation time for single-fiber PDS and PGACL stents compared with PLLA stents is presented in Figure 7b . The PDS stents began losing mechanical strength after 3 weeks of degradation, but preserved good strength for 6 weeks. In contrast, PGACL demonstrated a faster decrease in radial compression strength (the slope of the curve) that began immediately after exposure to the aqueous medium. This study thus indicates that PLLA stents can support body conduits for relatively long periods of time (20 weeks) and can therefore be used as endovascular stents, whereas PDS stents can afford good support for 5-6 weeks and PGACL stents can be applied for only 2 weeks. PDS and PGACL stents are therefore utilizable for short-term applications such as local support of the urinary track after surgery as well as after other interventions. In these cases, drug-eluting stents can be prepared using the methods described above for core/shell composite PLLA fibers. Incorporation of antiinflammatory agents in these stents may be beneficial.
Film-Based Stents
Drug-eluting film-based stents have been developed to support blood vessels and the trachea.
Vascular stents.
We demonstrated the successful transfer and expression of a nuclear-localizing ß-Gal reporter gene in cells in the arterial wall of rabbits after the implantation of biodegradable stents made of bioresorbable PLLA/PCL films creating a porous tubular structure impregnated with a recombinant adenovirus carrying that gene (100). Although we used a nonexpandable stent design, we demonstrated the exciting possibility of transferring genes that encode for key proteins in the central regulatory pathways of cell proliferation inside arterial wall cells, using bioresorbable stents as vehicles.
Vogt et al. (101) reported a novel PDLLA double-helical stent designed according to the material's properties, based on a finite element method. This stent was manufactured using the controlled expansion of saturated polymers (CESP) for molding the PDLLA. This method is characterized by a low process temperature that enables the processing of thermally sensitive polymers and the incorporation of biologically active substances. This stent exhibited sufficient mechanical stability and a significant potential to reduce restenosis after vascular intervention was observed following the incorporation of paclitaxel. Paclitaxel was shown to effectively inhibit proliferation and coronary stenosis in a pig model after vascular injury in a long-term course. The authors suggest that in vitro pharmacokinetics with a very slow release pattern of paclitaxel over a time span of more than 2 months might contribute to this favorable outcome. The authors also reported that paclitaxel loading did not increase toxicity, as reflected by media necrosis or delayed healing of endothelial cells.
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Alexis et al. (23) studied the in vitro release kinetics of paclitaxel and rapamycin from solution-cast PDLLA and PDLGA films and from nonexpandable helical stents prepared from strips cut from the films. The results demonstrated that the release mechanism for both drugs combined diffusion and degradation. The films and stents exhibited the same release profiles, indicating homogenous degradation kinetics. No burst effect was observed for either drug. This is especially important during paclitaxel administration, where cardiotoxicity is sometimes a concern. The authors also demonstrated that the release period can vary from one month to several months, depending on the matrix polymer.
PLLA tracheal stents. The metal stents currently used for blood vessel support can also serve for airway support (49, 50) . However, an ideal bioresorbable tracheal stent would support the neonatal trachea in tracheal malacia until the airway matures, and would then be totally resorbed, thus negating the need for a removal operation. We have developed a novel expandable stent prepared from a solution-cast PLLA-based film (73, 102) . The stent design is presented in Figure 8 . Dexamethasone (DM), a steroid antiinflammatory drug, is incorporated into this film-based stent to provide controlled local release of the drug during the mechanical support phase. In addition to its well-known antiinflammatory activity, DM has been demonstrated to inhibit the fibrotic response. Addition of this drug may therefore be helpful in the prevention of proliferative reactions, such as airway stenosis. This support structure was tested as a tracheal stent to support the tracheal airway and to treat tracheomalacia both in vitro and in vivo.
In vitro studies of the films and tracheal stents focused on their mechanical properties in light of the morphology and degradation and erosion processes. The PLLA films generally exhibited good initial mechanical properties. Exposure of the films to an aqueous medium resulted in decreased tensile strength, modulus, and ductility owing to chain scission and morphological changes. These films underwent some degradation and small changes in morphology during the 20 weeks of study, and retained good mechanical properties (73) .
Our PLLA tubular support structures (stents) developed from these films demonstrated good mechanical properties. Their initial radial compression strength (at least 200 KPa) was six times higher than the minimal strength required for supporting an infant trachea. The stent's radial compression strength is determined mainly by the polymer structure, whereas drug incorporation has a minor effect on the initial stent strength. Exposure to radial compression stress results in reversible elastic deformation of most stents, whereas certain stents prepared from relatively brittle polymer films exhibited a sudden brittle fracture. These stents retained good mechanical strength for at least 20 weeks in an aqueous medium at 37
• C (73). Incorporation of DM in the PLLA stents contributes to improved strength retention owing to the drug's stiffness and good dispersion. Preliminary in vivo studies of these stents demonstrated excellent proof of principle and tolerable biocompatibility.
Drug release from films used in tracheal stents. A method developed by us for controlling drug location/dispersion in the film was reported (102) and is described briefly in this section. Bioresorbable polymeric films containing DM were prepared using solution processing, accompanied by a postpreparation isothermal heat treatment. In this process, the kinetics of drug and polymer solidification are determined by the solvent evaporation rate and thus also the drug dispersion/location in the film. Solubility effects in the starting solution also contribute to the postcasting diffusion processes, and occur concomitantly to the drying step. In general, two types of www.annualreviews.org • Drug-Eluting Bioresorbable Stentspolymer/DM film structures were created and studied for all studied matrix polymer types, as presented in Figure 9 , for amorphous PDLGA/DM films:
1. A polymer film with large crystalline drug particles located on its surface, as presented in the upper micrograph of Figure 9 . This structure is derived from a dilute solution of both polymer and drug and was obtained using the slow solvent evaporation rate that enables prior drug nucleation and growth on the polymer solution surface. This skin formation is accompanied by later polymer core formation/solidification. This structure was named the A-type.
2. A polymer film with small drug particles and crystals distributed within the bulk, as presented in the lower micrograph of Figure 9 . This structure is derived from a concentrated solution and was obtained using the fast solvent evaporation rate and resulted from drug nucleation and segregation within a dense polymer solution. Solidification of drug and polymer occurred concomitantly. For semicrystalline-based films such as PLLA/DM, the drug is located in amorphous domains of a semicrystalline matrix, around the spherulites. This structure was named the B-type. We have studied these structures' morphologies and formation processes extensively, and a detailed model describing the structuring of these films is described elsewhere (102) . Investigation of these films focused on cumulative DM release as affected by film morphology (drug location/dispersion in the film) and degradation processes. The effect of the polymer's degree of crystallinity on the DM release profile was also studied (103) .
In general, the drug location/dispersion in the film and the polymer's weight loss rate determine the drug's release profile from the film. However, the DM release profile in certain cases of polymers with high degradation rates is determined mainly by the polymer's degradation, and the drug location/dispersion in the film has almost no effect on the release profile. All release profiles from A-type films exhibited an initial burst effect of approximately 30% (Figure 10a) . The hydrophobic nature of DM and the specific interactions between DM and the host polymer do not induce a higher burst effect. The second release stage from these films occurs at an approximately constant rate and is determined mainly by the polymer weight loss rate. In contrast, in most of the studied systems the matrix (monolithic) nature of the B-type film enabled release profiles that were determined mainly by the degradation profile of the host polymer, without any burst effect (Figure 10b) . It should be emphasized that all A-type films and some of the B-type films exhibited nearly constant DM release rates. Such release profiles are suitable for many applications, including the current application that focuses on bioresorbable tracheal stents built from these films. It was also found that a high degree of crystallinity contributes to slower drug release rates (compared with amorphous systems), mainly at relatively low weight losses. At high 
Figure 10
In vitro cumulative drug release from polymer/drug films: (a) A-type films, (b) B-type films. The host polymer is indicated.
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weight losses, where a porous structure is created, crystallinity has a minor effect on the rate of drug release. In addition to degradation and drug location/dispersion in the film, the porous structure that develops with degradation also affects the drug release profile from the films. For example, a fibrous pore structure probably enables more effective drug release than a spherical structure (103) .
CONCLUSIONS
This review presents an extensive overview of published studies of new stents with controlled release of drugs and proteins for endovascular, tracheal, and urethral applications. These fiber-and film-based devices combine a desired drug release behavior with good mechanical properties and can therefore be used to support various body conduits. Stents can therefore be used as drug/protein-delivery platforms in addition to their support function, releasing active agents from the stent in a desired controlled manner that can be used to enhance the healing of the surrounding tissues, increase the implant's biocompatibility, or even help cure certain diseases. The effect of fiber/film processing parameters on the microstructure and the resulting mechanical properties and release profiles must be elucidated. New designs based on composite fiber structures or structured films may thus advance the therapeutic field of supporting and healing body conduits.
